Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 922

1.

Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.

Dhawan D, Ramos-Vara JA, Stewart JC, Zheng R, Knapp DW.

Urol Oncol. 2009 May-Jun;27(3):284-92. doi: 10.1016/j.urolonc.2008.02.015.

PMID:
18562222
2.

Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines.

Bindels EM, Vermey M, De Both NJ, van der Kwast TH.

Virchows Arch. 2001 Oct;439(4):552-9.

PMID:
11710643
3.

Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.

Okamoto A, Shirakawa T, Bito T, Shigemura K, Hamada K, Gotoh A, Fujisawa M, Kawabata M.

Urology. 2008 Jan;71(1):156-60. doi: 10.1016/j.urology.2007.09.061.

PMID:
18242386
4.

Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies.

Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DM, Jankowski JA.

J Pathol. 2008 Jun;215(2):184-94. doi: 10.1002/path.2346.

PMID:
18393367
5.

Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder.

Shariat SF, Matsumoto K, Kim J, Ayala GE, Zhou JH, Jian W, Benedict WF, Lerner S.

J Urol. 2003 Sep;170(3):985-9.

PMID:
12913755
6.

Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice.

Dinney CP, Fishbeck R, Singh RK, Eve B, Pathak S, Brown N, Xie B, Fan D, Bucana CD, Fidler IJ, et al.

J Urol. 1995 Oct;154(4):1532-8.

PMID:
7658585
7.
8.

Genetic and phenotypic changes associated with the acquisition of tumorigenicity in human bladder cancer.

Gildea JJ, Golden WL, Harding MA, Theodorescu D.

Genes Chromosomes Cancer. 2000 Mar;27(3):252-63.

PMID:
10679914
9.

Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.

Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y.

J Urol. 2007 Feb;177(2):481-7; discussion 487.

PMID:
17222615
10.

Effects of the cyclooxygenase inhibitor, piroxicam, in combination with chemotherapy on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer.

Mohammed SI, Craig BA, Mutsaers AJ, Glickman NW, Snyder PW, deGortari AE, Schlittler DL, Coffman KT, Bonney PL, Knapp DW.

Mol Cancer Ther. 2003 Feb;2(2):183-8.

11.
12.

Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder.

Shariat SF, Kim JH, Ayala GE, Kho K, Wheeler TM, Lerner SP.

J Urol. 2003 Mar;169(3):938-42.

PMID:
12576817
13.

[Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].

Li C, Yan RP, Yuan GH, Feng YG, Wang JS, Gao X, Huang YS, Zhou JB, Xie SS.

Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):733-6. Chinese.

PMID:
17366782
14.

Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects.

Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J, Knapp DW.

Mol Cancer Ther. 2006 Feb;5(2):329-36.

15.

Reciprocal correlation between the expression of cyclooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas.

Jang TJ, Cha WH, Lee KS.

Virchows Arch. 2010 Sep;457(3):319-28. doi: 10.1007/s00428-010-0943-3.

PMID:
20582552
16.

Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes.

Sanchez-Carbayo M, Socci ND, Charytonowicz E, Lu M, Prystowsky M, Childs G, Cordon-Cardo C.

Cancer Res. 2002 Dec 1;62(23):6973-80.

17.

A new in vivo model to study invasion and metastasis of human bladder carcinoma.

Ahlering TE, Dubeau L, Jones PA.

Cancer Res. 1987 Dec 15;47(24 Pt 1):6660-5.

18.

Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells.

Dhawan D, Jeffreys AB, Zheng R, Stewart JC, Knapp DW.

Mol Cancer Ther. 2008 Apr;7(4):897-904. doi: 10.1158/1535-7163.MCT-07-0313.

19.

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma.

Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP, Young L, Shi SR, Gee C, Groshen S, Skinner DG, Cote RJ.

J Clin Oncol. 2004 Mar 15;22(6):1007-13.

PMID:
14981105
20.

E-cadherin promotes intraepithelial expansion of bladder carcinoma cells in an in vitro model of carcinoma in situ.

Bindels EM, Vermey M, van den Beemd R, Dinjens WN, Van Der Kwast TH.

Cancer Res. 2000 Jan 1;60(1):177-83.

Items per page

Supplemental Content

Support Center